Does Clinical Psychology Dismiss New Treatments Too Easily?

I’ve noticed that some clinical psychologists dismiss certain therapies outright due to a “lack of evidence,” but what actually counts as evidence seems pretty arbitrary. The replication crisis has shown that even many “gold standard” psychological treatments - like CBT - aren’t as empirically solid as once thought. Yet, some treatments (like EMDR, somatic therapy, or psychedelic-assisted therapy) get dismissed outright, even when replicated studies and real-world effectiveness suggest they work.

Psychology’s Evidence Problem

  • The replication crisis showed that many foundational psychology studies don’t hold up, yet clinical psychology continues relying on them.

  • CBT is still widely accepted despite research showing its effect sizes have declined over time (possibly due to inflated early results).

  • RCTs (randomized controlled trials) dominate treatment approval, even though they don’t always reflect real-world clinical practice.

Are Some Therapies Dismissed Due to Bias?

  • Many psychologists dismiss EMDR as “just exposure therapy plus distraction,” even though neuroimaging and memory reconsolidation research suggest it may function differently.

  • Psychedelic-assisted therapy was ignored for decades due to its countercultural associations, yet recent rigorous studies show profound efficacy for PTSD and depression.

  • Somatic and trauma-focused approaches are often called “woowoo,” despite growing evidence that the body plays a key role in processing trauma.

The Politics of “Evidence-Based” Treatments - “Evidence-based” often means “fits our current model” rather than “what actually helps patients.”

  • The medical and insurance model favors CBT and exposure therapy because they are structured, brief, and easy to study - not necessarily because they are the most effective for all patients.

  • Therapies that challenge traditional cognitive models (like IFS, somatic therapy, or EMDR) face resistance even when they show equal or better clinical outcomes.

The Field Needs More Open-Mindedness

  • If we accept that CBT and exposure therapy aren’t perfect, shouldn’t we also give newer approaches a fair evaluation?

  • The resistance to new models seems less about science and more about ideology, career incentives, and institutional power.

  • Psychologists should be pluralistic - supporting multiple treatment modalities as long as they are effective, instead of rigidly defending existing paradigms.

I’m curious - how do you think clinical psychology should balance skepticism with openness to new treatments? Is the field too quick to dismiss approaches that don’t fit the traditional cognitive-behavioral framework?